0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative

0
U.S. (TOLL FREE)
+1 (315) 215-3225
Communicable Diseases Drugs - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030
Published Date: September 2024
|
Report Code: QYRE-Auto-22V2583
Home | Market Reports | Health| Health Conditions| Infectious Diseases
COVID 19 Impact on Communicable Diseases Drugs Market Global Research Reports 2020 2021
BUY CHAPTERS

Communicable Diseases Drugs - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030

Code: QYRE-Auto-22V2583
Report
September 2024
Pages:131
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES

Communicable Diseases Drugs - Market Size

The global market for Communicable Diseases Drugs was estimated to be worth US$ 28160 million in 2023 and is forecast to a readjusted size of US$ 68580 million by 2030 with a CAGR of 6.6% during the forecast period 2024-2030

Communicable Diseases Drugs - Market

Communicable Diseases Drugs - Market

In this report, we study the drugs for Communicable Diseases. Communicable diseases are disorders caused by organisms — such as bacteria, viruses,fungi or parasites
The Communicable Diseases Treatment market refers to the pharmaceuticals and treatments used for the management and control of infectious diseases that can be transmitted from person to person. This market includes antiviral drugs, antibiotics, vaccines, and other therapies. The Communicable Diseases Treatment market has experienced significant growth due to factors such as the increasing prevalence of infectious diseases, the emergence of new pathogens, and the need for effective treatment options. Key players in the market include pharmaceutical companies, biotechnology firms, and government healthcare agencies. Geographically, the market is diverse, with regions facing different communicable disease burdens.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Communicable Diseases Drugs, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Communicable Diseases Drugs by region & country, by Type, and by Application.
The Communicable Diseases Drugs market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Communicable Diseases Drugs.
Market Segmentation

Scope of Communicable Diseases Drugs - Market Report

Report Metric Details
Report Name Communicable Diseases Drugs - Market
Forecasted market size in 2030 US$ 68580 million
CAGR 6.6%
Forecasted years 2024 - 2030
Segment by Type:
Segment by Application
  • Hospital
  • Clinic
  • Other
By Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia) Rest of Europe
  • Nordic Countries
  • Asia-Pacific (China, Japan, South Korea)
  • Southeast Asia (India, Australia)
  • Rest of Asia
  • Latin America (Mexico, Brazil)
  • Rest of Latin America
  • Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company Novartis, Gilead, GSK, Roche, Merck, Boehringer Ingelheim, Eli Lilly, AstraZeneca, J & J, Teva, AbbVie, Bausch Health, Abbott, Sanofi, Sun Pharma, Endo, Apotex, Amneal Pharma, Torrent Pharma
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

  • Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
  • Chapter 2: Detailed analysis of Communicable Diseases Drugs manufacturers competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
  • Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 5: Revenue of Communicable Diseases Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
  • Chapter 6: Revenue of Communicable Diseases Drugs in country level. It provides sigmate data by Type, and by Application for each country/region.
  • Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
  • Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
  • Chapter 9: Conclusion.

FAQ for this report

What is the Communicable Diseases Drugs - Market size in 2030?

Ans: The Communicable Diseases Drugs - Market size in 2030 will be US$ 68580 million.

Who are the main players in the Communicable Diseases Drugs - Market report?

Ans: The main players in the Communicable Diseases Drugs - Market are Novartis, Gilead, GSK, Roche, Merck, Boehringer Ingelheim, Eli Lilly, AstraZeneca, J & J, Teva, AbbVie, Bausch Health, Abbott, Sanofi, Sun Pharma, Endo, Apotex, Amneal Pharma, Torrent Pharma

What are the Application segmentation covered in the Communicable Diseases Drugs - Market report?

Ans: The Applications covered in the Communicable Diseases Drugs - Market report are Hospital, Clinic, Other

What are the Type segmentation covered in the Communicable Diseases Drugs - Market report?

Ans: The Types covered in the Communicable Diseases Drugs - Market report are HIV, Influenza, TB, Malaria, Hepatitis, HPV

Recommended Reports

Infectious Diseases Drugs

Tuberculosis & HIV

Vaccines & Delivery

1 Market Overview
1.1 Communicable Diseases Drugs Product Introduction
1.2 Global Communicable Diseases Drugs Market Size Forecast
1.3 Communicable Diseases Drugs Market Trends & Drivers
1.3.1 Communicable Diseases Drugs Industry Trends
1.3.2 Communicable Diseases Drugs Market Drivers & Opportunity
1.3.3 Communicable Diseases Drugs Market Challenges
1.3.4 Communicable Diseases Drugs Market Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Communicable Diseases Drugs Players Revenue Ranking (2023)
2.2 Global Communicable Diseases Drugs Revenue by Company (2019-2024)
2.3 Key Companies Communicable Diseases Drugs Manufacturing Base Distribution and Headquarters
2.4 Key Companies Communicable Diseases Drugs Product Offered
2.5 Key Companies Time to Begin Mass Production of Communicable Diseases Drugs
2.6 Communicable Diseases Drugs Market Competitive Analysis
2.6.1 Communicable Diseases Drugs Market Concentration Rate (2019-2024)
2.6.2 Global 5 and 10 Largest Companies by Communicable Diseases Drugs Revenue in 2023
2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Communicable Diseases Drugs as of 2023)
2.7 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 HIV
3.1.2 Influenza
3.1.3 TB
3.1.4 Malaria
3.1.5 Hepatitis
3.1.6 HPV
3.2 Global Communicable Diseases Drugs Sales Value by Type
3.2.1 Global Communicable Diseases Drugs Sales Value by Type (2019 VS 2023 VS 2030)
3.2.2 Global Communicable Diseases Drugs Sales Value, by Type (2019-2030)
3.2.3 Global Communicable Diseases Drugs Sales Value, by Type (%) (2019-2030)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Hospital
4.1.2 Clinic
4.1.3 Other
4.2 Global Communicable Diseases Drugs Sales Value by Application
4.2.1 Global Communicable Diseases Drugs Sales Value by Application (2019 VS 2023 VS 2030)
4.2.2 Global Communicable Diseases Drugs Sales Value, by Application (2019-2030)
4.2.3 Global Communicable Diseases Drugs Sales Value, by Application (%) (2019-2030)
5 Segmentation by Region
5.1 Global Communicable Diseases Drugs Sales Value by Region
5.1.1 Global Communicable Diseases Drugs Sales Value by Region: 2019 VS 2023 VS 2030
5.1.2 Global Communicable Diseases Drugs Sales Value by Region (2019-2024)
5.1.3 Global Communicable Diseases Drugs Sales Value by Region (2025-2030)
5.1.4 Global Communicable Diseases Drugs Sales Value by Region (%), (2019-2030)
5.2 North America
5.2.1 North America Communicable Diseases Drugs Sales Value, 2019-2030
5.2.2 North America Communicable Diseases Drugs Sales Value by Country (%), 2023 VS 2030
5.3 Europe
5.3.1 Europe Communicable Diseases Drugs Sales Value, 2019-2030
5.3.2 Europe Communicable Diseases Drugs Sales Value by Country (%), 2023 VS 2030
5.4 Asia Pacific
5.4.1 Asia Pacific Communicable Diseases Drugs Sales Value, 2019-2030
5.4.2 Asia Pacific Communicable Diseases Drugs Sales Value by Country (%), 2023 VS 2030
5.5 South America
5.5.1 South America Communicable Diseases Drugs Sales Value, 2019-2030
5.5.2 South America Communicable Diseases Drugs Sales Value by Country (%), 2023 VS 2030
5.6 Middle East & Africa
5.6.1 Middle East & Africa Communicable Diseases Drugs Sales Value, 2019-2030
5.6.2 Middle East & Africa Communicable Diseases Drugs Sales Value by Country (%), 2023 VS 2030
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Communicable Diseases Drugs Sales Value Growth Trends, 2019 VS 2023 VS 2030
6.2 Key Countries/Regions Communicable Diseases Drugs Sales Value
6.3 United States
6.3.1 United States Communicable Diseases Drugs Sales Value, 2019-2030
6.3.2 United States Communicable Diseases Drugs Sales Value by Type (%), 2023 VS 2030
6.3.3 United States Communicable Diseases Drugs Sales Value by Application, 2023 VS 2030
6.4 Europe
6.4.1 Europe Communicable Diseases Drugs Sales Value, 2019-2030
6.4.2 Europe Communicable Diseases Drugs Sales Value by Type (%), 2023 VS 2030
6.4.3 Europe Communicable Diseases Drugs Sales Value by Application, 2023 VS 2030
6.5 China
6.5.1 China Communicable Diseases Drugs Sales Value, 2019-2030
6.5.2 China Communicable Diseases Drugs Sales Value by Type (%), 2023 VS 2030
6.5.3 China Communicable Diseases Drugs Sales Value by Application, 2023 VS 2030
6.6 Japan
6.6.1 Japan Communicable Diseases Drugs Sales Value, 2019-2030
6.6.2 Japan Communicable Diseases Drugs Sales Value by Type (%), 2023 VS 2030
6.6.3 Japan Communicable Diseases Drugs Sales Value by Application, 2023 VS 2030
6.7 South Korea
6.7.1 South Korea Communicable Diseases Drugs Sales Value, 2019-2030
6.7.2 South Korea Communicable Diseases Drugs Sales Value by Type (%), 2023 VS 2030
6.7.3 South Korea Communicable Diseases Drugs Sales Value by Application, 2023 VS 2030
6.8 Southeast Asia
6.8.1 Southeast Asia Communicable Diseases Drugs Sales Value, 2019-2030
6.8.2 Southeast Asia Communicable Diseases Drugs Sales Value by Type (%), 2023 VS 2030
6.8.3 Southeast Asia Communicable Diseases Drugs Sales Value by Application, 2023 VS 2030
6.9 India
6.9.1 India Communicable Diseases Drugs Sales Value, 2019-2030
6.9.2 India Communicable Diseases Drugs Sales Value by Type (%), 2023 VS 2030
6.9.3 India Communicable Diseases Drugs Sales Value by Application, 2023 VS 2030
7 Company Profiles
7.1 Novartis
7.1.1 Novartis Profile
7.1.2 Novartis Main Business
7.1.3 Novartis Communicable Diseases Drugs Products, Services and Solutions
7.1.4 Novartis Communicable Diseases Drugs Revenue (US$ Million) & (2019-2024)
7.1.5 Novartis Recent Developments
7.2 Gilead
7.2.1 Gilead Profile
7.2.2 Gilead Main Business
7.2.3 Gilead Communicable Diseases Drugs Products, Services and Solutions
7.2.4 Gilead Communicable Diseases Drugs Revenue (US$ Million) & (2019-2024)
7.2.5 Gilead Recent Developments
7.3 GSK
7.3.1 GSK Profile
7.3.2 GSK Main Business
7.3.3 GSK Communicable Diseases Drugs Products, Services and Solutions
7.3.4 GSK Communicable Diseases Drugs Revenue (US$ Million) & (2019-2024)
7.3.5 Roche Recent Developments
7.4 Roche
7.4.1 Roche Profile
7.4.2 Roche Main Business
7.4.3 Roche Communicable Diseases Drugs Products, Services and Solutions
7.4.4 Roche Communicable Diseases Drugs Revenue (US$ Million) & (2019-2024)
7.4.5 Roche Recent Developments
7.5 Merck
7.5.1 Merck Profile
7.5.2 Merck Main Business
7.5.3 Merck Communicable Diseases Drugs Products, Services and Solutions
7.5.4 Merck Communicable Diseases Drugs Revenue (US$ Million) & (2019-2024)
7.5.5 Merck Recent Developments
7.6 Boehringer Ingelheim
7.6.1 Boehringer Ingelheim Profile
7.6.2 Boehringer Ingelheim Main Business
7.6.3 Boehringer Ingelheim Communicable Diseases Drugs Products, Services and Solutions
7.6.4 Boehringer Ingelheim Communicable Diseases Drugs Revenue (US$ Million) & (2019-2024)
7.6.5 Boehringer Ingelheim Recent Developments
7.7 Eli Lilly
7.7.1 Eli Lilly Profile
7.7.2 Eli Lilly Main Business
7.7.3 Eli Lilly Communicable Diseases Drugs Products, Services and Solutions
7.7.4 Eli Lilly Communicable Diseases Drugs Revenue (US$ Million) & (2019-2024)
7.7.5 Eli Lilly Recent Developments
7.8 AstraZeneca
7.8.1 AstraZeneca Profile
7.8.2 AstraZeneca Main Business
7.8.3 AstraZeneca Communicable Diseases Drugs Products, Services and Solutions
7.8.4 AstraZeneca Communicable Diseases Drugs Revenue (US$ Million) & (2019-2024)
7.8.5 AstraZeneca Recent Developments
7.9 J & J
7.9.1 J & J Profile
7.9.2 J & J Main Business
7.9.3 J & J Communicable Diseases Drugs Products, Services and Solutions
7.9.4 J & J Communicable Diseases Drugs Revenue (US$ Million) & (2019-2024)
7.9.5 J & J Recent Developments
7.10 Teva
7.10.1 Teva Profile
7.10.2 Teva Main Business
7.10.3 Teva Communicable Diseases Drugs Products, Services and Solutions
7.10.4 Teva Communicable Diseases Drugs Revenue (US$ Million) & (2019-2024)
7.10.5 Teva Recent Developments
7.11 AbbVie
7.11.1 AbbVie Profile
7.11.2 AbbVie Main Business
7.11.3 AbbVie Communicable Diseases Drugs Products, Services and Solutions
7.11.4 AbbVie Communicable Diseases Drugs Revenue (US$ Million) & (2019-2024)
7.11.5 AbbVie Recent Developments
7.12 Bausch Health
7.12.1 Bausch Health Profile
7.12.2 Bausch Health Main Business
7.12.3 Bausch Health Communicable Diseases Drugs Products, Services and Solutions
7.12.4 Bausch Health Communicable Diseases Drugs Revenue (US$ Million) & (2019-2024)
7.12.5 Bausch Health Recent Developments
7.13 Abbott
7.13.1 Abbott Profile
7.13.2 Abbott Main Business
7.13.3 Abbott Communicable Diseases Drugs Products, Services and Solutions
7.13.4 Abbott Communicable Diseases Drugs Revenue (US$ Million) & (2019-2024)
7.13.5 Abbott Recent Developments
7.14 Sanofi
7.14.1 Sanofi Profile
7.14.2 Sanofi Main Business
7.14.3 Sanofi Communicable Diseases Drugs Products, Services and Solutions
7.14.4 Sanofi Communicable Diseases Drugs Revenue (US$ Million) & (2019-2024)
7.14.5 Sanofi Recent Developments
7.15 Sun Pharma
7.15.1 Sun Pharma Profile
7.15.2 Sun Pharma Main Business
7.15.3 Sun Pharma Communicable Diseases Drugs Products, Services and Solutions
7.15.4 Sun Pharma Communicable Diseases Drugs Revenue (US$ Million) & (2019-2024)
7.15.5 Sun Pharma Recent Developments
7.16 Endo
7.16.1 Endo Profile
7.16.2 Endo Main Business
7.16.3 Endo Communicable Diseases Drugs Products, Services and Solutions
7.16.4 Endo Communicable Diseases Drugs Revenue (US$ Million) & (2019-2024)
7.16.5 Endo Recent Developments
7.17 Apotex
7.17.1 Apotex Profile
7.17.2 Apotex Main Business
7.17.3 Apotex Communicable Diseases Drugs Products, Services and Solutions
7.17.4 Apotex Communicable Diseases Drugs Revenue (US$ Million) & (2019-2024)
7.17.5 Apotex Recent Developments
7.18 Amneal Pharma
7.18.1 Amneal Pharma Profile
7.18.2 Amneal Pharma Main Business
7.18.3 Amneal Pharma Communicable Diseases Drugs Products, Services and Solutions
7.18.4 Amneal Pharma Communicable Diseases Drugs Revenue (US$ Million) & (2019-2024)
7.18.5 Amneal Pharma Recent Developments
7.19 Torrent Pharma
7.19.1 Torrent Pharma Profile
7.19.2 Torrent Pharma Main Business
7.19.3 Torrent Pharma Communicable Diseases Drugs Products, Services and Solutions
7.19.4 Torrent Pharma Communicable Diseases Drugs Revenue (US$ Million) & (2019-2024)
7.19.5 Torrent Pharma Recent Developments
8 Industry Chain Analysis
8.1 Communicable Diseases Drugs Industrial Chain
8.2 Communicable Diseases Drugs Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 Communicable Diseases Drugs Sales Model
8.5.2 Sales Channel
8.5.3 Communicable Diseases Drugs Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.2 Data Source
10.2 Author Details
10.3 Disclaimer
List of Tables
    Table 1. Communicable Diseases Drugs Market Trends
    Table 2. Communicable Diseases Drugs Market Drivers & Opportunity
    Table 3. Communicable Diseases Drugs Market Challenges
    Table 4. Communicable Diseases Drugs Market Restraints
    Table 5. Global Communicable Diseases Drugs Revenue by Company (2019-2024) & (US$ Million)
    Table 6. Global Communicable Diseases Drugs Revenue Market Share by Company (2019-2024)
    Table 7. Key Companies Communicable Diseases Drugs Manufacturing Base Distribution and Headquarters
    Table 8. Key Companies Communicable Diseases Drugs Product Type
    Table 9. Key Companies Time to Begin Mass Production of Communicable Diseases Drugs
    Table 10. Global Communicable Diseases Drugs Companies Market Concentration Ratio (CR5 and HHI)
    Table 11. Global Top Companies Market Share by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Communicable Diseases Drugs as of 2023)
    Table 12. Mergers & Acquisitions, Expansion Plans
    Table 13. Global Communicable Diseases Drugs Sales Value by Type: 2019 VS 2023 VS 2030 (US$ Million)
    Table 14. Global Communicable Diseases Drugs Sales Value by Type (2019-2024) & (US$ Million)
    Table 15. Global Communicable Diseases Drugs Sales Value by Type (2025-2030) & (US$ Million)
    Table 16. Global Communicable Diseases Drugs Sales Market Share in Value by Type (2019-2024) & (%)
    Table 17. Global Communicable Diseases Drugs Sales Market Share in Value by Type (2025-2030) & (%)
    Table 18. Global Communicable Diseases Drugs Sales Value by Application: 2019 VS 2023 VS 2030 (US$ Million)
    Table 19. Global Communicable Diseases Drugs Sales Value by Application (2019-2024) & (US$ Million)
    Table 20. Global Communicable Diseases Drugs Sales Value by Application (2025-2030) & (US$ Million)
    Table 21. Global Communicable Diseases Drugs Sales Market Share in Value by Application (2019-2024) & (%)
    Table 22. Global Communicable Diseases Drugs Sales Market Share in Value by Application (2025-2030) & (%)
    Table 23. Global Communicable Diseases Drugs Sales Value by Region: 2019 VS 2023 VS 2030 (US$ Million)
    Table 24. Global Communicable Diseases Drugs Sales Value by Region (2019-2024) & (US$ Million)
    Table 25. Global Communicable Diseases Drugs Sales Value by Region (2025-2030) & (US$ Million)
    Table 26. Global Communicable Diseases Drugs Sales Value by Region (2019-2024) & (%)
    Table 27. Global Communicable Diseases Drugs Sales Value by Region (2025-2030) & (%)
    Table 28. Key Countries/Regions Communicable Diseases Drugs Sales Value Growth Trends, (US$ Million): 2019 VS 2023 VS 2030
    Table 29. Key Countries/Regions Communicable Diseases Drugs Sales Value, (2019-2024) & (US$ Million)
    Table 30. Key Countries/Regions Communicable Diseases Drugs Sales Value, (2025-2030) & (US$ Million)
    Table 31. Novartis Basic Information List
    Table 32. Novartis Description and Business Overview
    Table 33. Novartis Communicable Diseases Drugs Products, Services and Solutions
    Table 34. Revenue (US$ Million) in Communicable Diseases Drugs Business of Novartis (2019-2024)
    Table 35. Novartis Recent Developments
    Table 36. Gilead Basic Information List
    Table 37. Gilead Description and Business Overview
    Table 38. Gilead Communicable Diseases Drugs Products, Services and Solutions
    Table 39. Revenue (US$ Million) in Communicable Diseases Drugs Business of Gilead (2019-2024)
    Table 40. Gilead Recent Developments
    Table 41. GSK Basic Information List
    Table 42. GSK Description and Business Overview
    Table 43. GSK Communicable Diseases Drugs Products, Services and Solutions
    Table 44. Revenue (US$ Million) in Communicable Diseases Drugs Business of GSK (2019-2024)
    Table 45. GSK Recent Developments
    Table 46. Roche Basic Information List
    Table 47. Roche Description and Business Overview
    Table 48. Roche Communicable Diseases Drugs Products, Services and Solutions
    Table 49. Revenue (US$ Million) in Communicable Diseases Drugs Business of Roche (2019-2024)
    Table 50. Roche Recent Developments
    Table 51. Merck Basic Information List
    Table 52. Merck Description and Business Overview
    Table 53. Merck Communicable Diseases Drugs Products, Services and Solutions
    Table 54. Revenue (US$ Million) in Communicable Diseases Drugs Business of Merck (2019-2024)
    Table 55. Merck Recent Developments
    Table 56. Boehringer Ingelheim Basic Information List
    Table 57. Boehringer Ingelheim Description and Business Overview
    Table 58. Boehringer Ingelheim Communicable Diseases Drugs Products, Services and Solutions
    Table 59. Revenue (US$ Million) in Communicable Diseases Drugs Business of Boehringer Ingelheim (2019-2024)
    Table 60. Boehringer Ingelheim Recent Developments
    Table 61. Eli Lilly Basic Information List
    Table 62. Eli Lilly Description and Business Overview
    Table 63. Eli Lilly Communicable Diseases Drugs Products, Services and Solutions
    Table 64. Revenue (US$ Million) in Communicable Diseases Drugs Business of Eli Lilly (2019-2024)
    Table 65. Eli Lilly Recent Developments
    Table 66. AstraZeneca Basic Information List
    Table 67. AstraZeneca Description and Business Overview
    Table 68. AstraZeneca Communicable Diseases Drugs Products, Services and Solutions
    Table 69. Revenue (US$ Million) in Communicable Diseases Drugs Business of AstraZeneca (2019-2024)
    Table 70. AstraZeneca Recent Developments
    Table 71. J & J Basic Information List
    Table 72. J & J Description and Business Overview
    Table 73. J & J Communicable Diseases Drugs Products, Services and Solutions
    Table 74. Revenue (US$ Million) in Communicable Diseases Drugs Business of J & J (2019-2024)
    Table 75. J & J Recent Developments
    Table 76. Teva Basic Information List
    Table 77. Teva Description and Business Overview
    Table 78. Teva Communicable Diseases Drugs Products, Services and Solutions
    Table 79. Revenue (US$ Million) in Communicable Diseases Drugs Business of Teva (2019-2024)
    Table 80. Teva Recent Developments
    Table 81. AbbVie Basic Information List
    Table 82. AbbVie Description and Business Overview
    Table 83. AbbVie Communicable Diseases Drugs Products, Services and Solutions
    Table 84. Revenue (US$ Million) in Communicable Diseases Drugs Business of AbbVie (2019-2024)
    Table 85. AbbVie Recent Developments
    Table 86. Bausch Health Basic Information List
    Table 87. Bausch Health Description and Business Overview
    Table 88. Bausch Health Communicable Diseases Drugs Products, Services and Solutions
    Table 89. Revenue (US$ Million) in Communicable Diseases Drugs Business of Bausch Health (2019-2024)
    Table 90. Bausch Health Recent Developments
    Table 91. Abbott Basic Information List
    Table 92. Abbott Description and Business Overview
    Table 93. Abbott Communicable Diseases Drugs Products, Services and Solutions
    Table 94. Revenue (US$ Million) in Communicable Diseases Drugs Business of Abbott (2019-2024)
    Table 95. Abbott Recent Developments
    Table 96. Sanofi Basic Information List
    Table 97. Sanofi Description and Business Overview
    Table 98. Sanofi Communicable Diseases Drugs Products, Services and Solutions
    Table 99. Revenue (US$ Million) in Communicable Diseases Drugs Business of Sanofi (2019-2024)
    Table 100. Sanofi Recent Developments
    Table 101. Sun Pharma Basic Information List
    Table 102. Sun Pharma Description and Business Overview
    Table 103. Sun Pharma Communicable Diseases Drugs Products, Services and Solutions
    Table 104. Revenue (US$ Million) in Communicable Diseases Drugs Business of Sun Pharma (2019-2024)
    Table 105. Sun Pharma Recent Developments
    Table 106. Endo Basic Information List
    Table 107. Endo Description and Business Overview
    Table 108. Endo Communicable Diseases Drugs Products, Services and Solutions
    Table 109. Revenue (US$ Million) in Communicable Diseases Drugs Business of Endo (2019-2024)
    Table 110. Endo Recent Developments
    Table 111. Apotex Basic Information List
    Table 112. Apotex Description and Business Overview
    Table 113. Apotex Communicable Diseases Drugs Products, Services and Solutions
    Table 114. Revenue (US$ Million) in Communicable Diseases Drugs Business of Apotex (2019-2024)
    Table 115. Apotex Recent Developments
    Table 116. Amneal Pharma Basic Information List
    Table 117. Amneal Pharma Description and Business Overview
    Table 118. Amneal Pharma Communicable Diseases Drugs Products, Services and Solutions
    Table 119. Revenue (US$ Million) in Communicable Diseases Drugs Business of Amneal Pharma (2019-2024)
    Table 120. Amneal Pharma Recent Developments
    Table 121. Torrent Pharma Basic Information List
    Table 122. Torrent Pharma Description and Business Overview
    Table 123. Torrent Pharma Communicable Diseases Drugs Products, Services and Solutions
    Table 124. Revenue (US$ Million) in Communicable Diseases Drugs Business of Torrent Pharma (2019-2024)
    Table 125. Torrent Pharma Recent Developments
    Table 126. Key Raw Materials Lists
    Table 127. Raw Materials Key Suppliers Lists
    Table 128. Communicable Diseases Drugs Downstream Customers
    Table 129. Communicable Diseases Drugs Distributors List
    Table 130. Research Programs/Design for This Report
    Table 131. Key Data Information from Secondary Sources
    Table 132. Key Data Information from Primary Sources
    Table 133. Business Unit and Senior & Team Lead Analysts
List of Figures
    Figure 1. Communicable Diseases Drugs Product Picture
    Figure 2. Global Communicable Diseases Drugs Sales Value, 2019 VS 2023 VS 2030 (US$ Million)
    Figure 3. Global Communicable Diseases Drugs Sales Value (2019-2030) & (US$ Million)
    Figure 4. Communicable Diseases Drugs Report Years Considered
    Figure 5. Global Communicable Diseases Drugs Players Revenue Ranking (2023) & (US$ Million)
    Figure 6. The 5 and 10 Largest Manufacturers in the World: Market Share by Communicable Diseases Drugs Revenue in 2023
    Figure 7. Communicable Diseases Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023
    Figure 8. HIV Picture
    Figure 9. Influenza Picture
    Figure 10. TB Picture
    Figure 11. Malaria Picture
    Figure 12. Hepatitis Picture
    Figure 13. HPV Picture
    Figure 14. Global Communicable Diseases Drugs Sales Value by Type (2019 VS 2023 VS 2030) & (US$ Million)
    Figure 15. Global Communicable Diseases Drugs Sales Value Market Share by Type, 2023 & 2030
    Figure 16. Product Picture of Hospital
    Figure 17. Product Picture of Clinic
    Figure 18. Product Picture of Other
    Figure 19. Global Communicable Diseases Drugs Sales Value by Application (2019 VS 2023 VS 2030) & (US$ Million)
    Figure 20. Global Communicable Diseases Drugs Sales Value Market Share by Application, 2023 & 2030
    Figure 21. North America Communicable Diseases Drugs Sales Value (2019-2030) & (US$ Million)
    Figure 22. North America Communicable Diseases Drugs Sales Value by Country (%), 2023 VS 2030
    Figure 23. Europe Communicable Diseases Drugs Sales Value (2019-2030) & (US$ Million)
    Figure 24. Europe Communicable Diseases Drugs Sales Value by Country (%), 2023 VS 2030
    Figure 25. Asia Pacific Communicable Diseases Drugs Sales Value (2019-2030) & (US$ Million)
    Figure 26. Asia Pacific Communicable Diseases Drugs Sales Value by Country (%), 2023 VS 2030
    Figure 27. South America Communicable Diseases Drugs Sales Value (2019-2030) & (US$ Million)
    Figure 28. South America Communicable Diseases Drugs Sales Value by Country (%), 2023 VS 2030
    Figure 29. Middle East & Africa Communicable Diseases Drugs Sales Value (2019-2030) & (US$ Million)
    Figure 30. Middle East & Africa Communicable Diseases Drugs Sales Value by Country (%), 2023 VS 2030
    Figure 31. Key Countries/Regions Communicable Diseases Drugs Sales Value (%), (2019-2030)
    Figure 32. United States Communicable Diseases Drugs Sales Value, (2019-2030) & (US$ Million)
    Figure 33. United States Communicable Diseases Drugs Sales Value by Type (%), 2023 VS 2030
    Figure 34. United States Communicable Diseases Drugs Sales Value by Application (%), 2023 VS 2030
    Figure 35. Europe Communicable Diseases Drugs Sales Value, (2019-2030) & (US$ Million)
    Figure 36. Europe Communicable Diseases Drugs Sales Value by Type (%), 2023 VS 2030
    Figure 37. Europe Communicable Diseases Drugs Sales Value by Application (%), 2023 VS 2030
    Figure 38. China Communicable Diseases Drugs Sales Value, (2019-2030) & (US$ Million)
    Figure 39. China Communicable Diseases Drugs Sales Value by Type (%), 2023 VS 2030
    Figure 40. China Communicable Diseases Drugs Sales Value by Application (%), 2023 VS 2030
    Figure 41. Japan Communicable Diseases Drugs Sales Value, (2019-2030) & (US$ Million)
    Figure 42. Japan Communicable Diseases Drugs Sales Value by Type (%), 2023 VS 2030
    Figure 43. Japan Communicable Diseases Drugs Sales Value by Application (%), 2023 VS 2030
    Figure 44. South Korea Communicable Diseases Drugs Sales Value, (2019-2030) & (US$ Million)
    Figure 45. South Korea Communicable Diseases Drugs Sales Value by Type (%), 2023 VS 2030
    Figure 46. South Korea Communicable Diseases Drugs Sales Value by Application (%), 2023 VS 2030
    Figure 47. Southeast Asia Communicable Diseases Drugs Sales Value, (2019-2030) & (US$ Million)
    Figure 48. Southeast Asia Communicable Diseases Drugs Sales Value by Type (%), 2023 VS 2030
    Figure 49. Southeast Asia Communicable Diseases Drugs Sales Value by Application (%), 2023 VS 2030
    Figure 50. India Communicable Diseases Drugs Sales Value, (2019-2030) & (US$ Million)
    Figure 51. India Communicable Diseases Drugs Sales Value by Type (%), 2023 VS 2030
    Figure 52. India Communicable Diseases Drugs Sales Value by Application (%), 2023 VS 2030
    Figure 53. Communicable Diseases Drugs Industrial Chain
    Figure 54. Communicable Diseases Drugs Manufacturing Cost Structure
    Figure 55. Channels of Distribution (Direct Sales, and Distribution)
    Figure 56. Bottom-up and Top-down Approaches for This Report
    Figure 57. Data Triangulation
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$3950

This license allows only one user to access the PDF.
Electronic (PDF)

$5925

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$7900

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)

OUR CUSTOMER

SIS Group of Schools

SIMILAR REPORTS

RELATED REPORTS

Global Hepatitis B Virus Core Antibody Diagnostic Kits Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-21N6899
Wed Sep 10 00:00:00 UTC 2025

Add to Cart

Global Pediatric Vaccines Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-13M6952
Wed Sep 10 00:00:00 UTC 2025

Add to Cart

Global Poliomyelitis Vaccines Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-29X7355
Tue Sep 09 00:00:00 UTC 2025

Add to Cart

Global Varicella Virus (Chickenpox) Vaccine Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-28B293
Tue Sep 09 00:00:00 UTC 2025

Add to Cart